B13- The Impact of Nonprescription Medicines labelling on Consumers

When developing product labels, do we spend enough time thinking about the impact of our choices on the consumer, our intended audience? Assuming most attendees are familiar with the content, this session will revisit the ‘Usability Guidelines’ asking the question ‘Why?’.   The session will also look at recent research into consumer perceptions of therapeutic goods labelling – have they been impacted by the availability via the web of increasing volumes of information?

Chairperson: Lydia Purvis, Bayer